Prompted to email Biotron enquiries, see where it leads....
Hi,It's become apparent that your recent reports on Phase II trials have missed your communicated deadlines which you have stated in a number of past announcements via the following wording such as "imminent", "several weeks", "coming weeks", "expected shortly", "near-term" and "late 2023".26/09/2023 Letter to Shareholders - Pg 2 Release of headline data is expected in coming weeks.20/10/2023 Annual Report and Notice of AGM
- Pg 4 Preliminary results from the BIT225-012 COVID-19 trial are expected to be available in September 2023.
- Pg 5 preliminary results from the HIV-1 trials are anticipated to be available in the third quarter of 2023.
24/10/2023 Presentation to Investors -
- Pg 4 The headline results from three human Phase 2 clinical trials are expected in coming weeks.
- Pg 6 * Headline results expected late 2023
- Pg 7 and pg 8 Headline results for all three trials expected late 2023
- Pg 9 Results expected late 2023
- Pg 11 SARS-CoV-2/COVID-19 program provides further value for BIT225 with results from the completed Phase 2 COVID-10clinical trial expected shortly
- Pg 11 • Results from three Phase 2 trials will be significant near-term milestones
23/11/2023 Presentation to Annual General Meeting
- Pg 1 Results are imminent.
14/12/2023 Shareholder update - Pg 1 We look forward with confidence to releasing the results of the three clinical trials in coming weeks.I would expect that Biotron needs to provide greater granularity and visibility on the status of results given the wording on when results are released. If that analysis is the result of laboratory delays or positive/negative partnering for Phase III then this should be stated with greater regularity so investors have an opportunity to make an informed decision on whether they continue to support Biotron or not.It is noted that you mention shareholder frustration in the Chairman's address at the AGM, though the language used around delivery of results appears to be inconsistent and borderline manipulative given the ambiguity of such wording.Right now a significant number of investors such as myself are frustrated and becoming more impatient by the delays given the lack of communications.Regards,
